Profile data is unavailable for this security.
About the company
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
- Revenue in USD (TTM)0.00
- Net income in USD-25.43m
- Incorporated2019
- Employees13.00
- LocationGalecto Inc75 State Street, Suite 100BOSTON 02109United StatesUSA
- Fax+1 (302) 655-5049
- Websitehttps://galecto.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transcode Therapeutics Inc | 0.00 | -17.91m | 8.33m | 10.00 | -- | 2.65 | -- | -- | -75.48 | -75.48 | 0.00 | 0.182 | 0.00 | -- | -- | 0.00 | -334.48 | -133.14 | -973.00 | -181.26 | -- | -- | -- | -- | -- | -90.11 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -17.57m | 8.48m | 85.00 | -- | 0.3581 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Calidi Biotherapeutics Inc | 0.00 | -24.92m | 8.73m | 41.00 | -- | -- | -- | -- | -5.41 | -5.41 | 0.00 | -1.82 | 0.00 | -- | -- | 0.00 | -279.89 | -- | -- | -- | -- | -- | -- | -- | -- | -27.58 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -137.05m | 8.77m | 16.00 | -- | -- | -- | 38.80 | -138.17 | -138.17 | 0.2557 | 6.03 | 0.0092 | -- | 12.91 | 14,125.00 | -557.63 | -63.43 | -896.39 | -85.72 | -- | -- | -60,641.15 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 79.57k | -18.38m | 8.88m | 8.00 | -- | 1.68 | -- | 111.63 | -2.93 | -2.93 | 0.0126 | 0.7063 | 0.0051 | -- | -- | 9,946.25 | -117.93 | -66.49 | -148.63 | -85.55 | -- | -- | -23,102.16 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Soligenix Inc | 494.62k | -7.04m | 9.21m | 13.00 | -- | 1.80 | -- | 18.63 | -9.58 | -9.58 | 0.6152 | 2.25 | 0.0418 | -- | 8.70 | 38,047.69 | -59.45 | -75.40 | -121.64 | -154.32 | 8.75 | 22.83 | -1,423.81 | -620.02 | -- | -- | 0.4421 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -45.34m | 9.27m | 40.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | 0.0678 | 0.00 | -- | -- | 0.00 | -83.82 | -86.35 | -140.98 | -106.38 | -- | -- | -- | -11,853.94 | -- | -59.78 | 0.8753 | -- | -- | -- | -3.78 | -- | -- | -- |
| BioCardia Inc | 428.00k | -8.56m | 9.28m | 16.00 | -- | -- | -- | 21.68 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Galecto Inc | 0.00 | -25.43m | 9.35m | 13.00 | -- | 0.3445 | -- | -- | -23.45 | -23.45 | 0.00 | 21.74 | 0.00 | -- | -- | 0.00 | -59.06 | -48.46 | -75.34 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Molecular Templates Inc | 25.47m | -15.63m | 9.36m | 62.00 | -- | 1.32 | -- | 0.3674 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| GlycoMimetics Inc | 10.00k | -39.11m | 9.85m | 35.00 | -- | 0.4911 | -- | 985.31 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 9.94m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 16.02m | 2.67m | 10.22m | 12.00 | -- | 0.3087 | 3.79 | 0.6379 | -7.76 | -7.76 | 6.61 | 11.14 | 0.5279 | -- | 7.16 | 1,335,000.00 | 10.54 | -70.52 | 11.20 | -81.86 | -- | -- | 19.98 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | 0.00 | -5.17m | 10.22m | 7.00 | -- | -- | -- | -- | -0.0667 | -0.0667 | 0.00 | -0.0738 | 0.00 | -- | -- | 0.00 | -312.39 | -- | -- | -- | -- | -- | -- | -- | -- | -21.32 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
| BioVie Inc | 0.00 | -33.01m | 10.30m | 14.00 | -- | 0.515 | -- | -- | -7.92 | -7.92 | 0.00 | 2.51 | 0.00 | -- | -- | 0.00 | -106.51 | -330.64 | -176.17 | -875.72 | -- | -- | -- | -- | -- | -- | 0.2688 | -- | -- | -- | 34.32 | -- | -- | -- |
Data as of Oct 09 2024. Currency figures normalised to Galecto Inc's reporting currency: US Dollar USD
4.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 30 Jun 2024 | 579.30k | 2.14% |
| Geode Capital Management LLCas of 30 Jun 2024 | 214.13k | 0.79% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 212.69k | 0.78% |
| Citadel Securities LLCas of 31 Mar 2024 | 93.50k | 0.35% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 73.10k | 0.27% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 48.03k | 0.18% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 44.91k | 0.17% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 30.40k | 0.11% |
| Jane Street Capital LLCas of 31 Mar 2024 | 26.21k | 0.10% |
| Summit Trail Advisors LLCas of 31 Mar 2024 | 25.00k | 0.09% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
